Fig. 7
From: Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein
Effect of F11R/JAM-A-derived peptide (P4D) on metastasis in 4T1 mouse breast cancer model. The peptide P4D decreases the breast cancer metastasis to the lungs in mice. The mice were treated for 21 days with daily injections of 4 mg P4D (group 1), 0.4 mg P4D (group 2) or vehicle (0.9% saline, group 3). Representative hematoxylin and eosin stained images of metastases in the 4T1 mouse breast cancer model are shown. A: lung parenchyma without metastases. B–C: Lung parenchyma with small metastases (B: group 1, C: group 2). D: Massive metastases to the lung (group 3). Metastases are indicated by red arrows. Magnification of 400 × . E: F11R/JAM-A antigen level in blood plasma from 4T1 control mice and mice treated with two concentrations of peptide 4D. The data do not fall upon Gaussian distribution as tested by Shapiro–Wilk normality W test (P-values for Control: 0.8942, for P4D 0.4 mg: 0.6287, for P4D 4.0 mg: 0.0119). As estimated by Kruskall-Wallis test (P = 0.0081) the mean values of F11R/JAM-A level in murine plasma different significantly between the groups. Dunn’s multiple comparisons test revealed, that the significant differences are found for P4D 0.4 mg vs. Control (P = 0.0486), and for P4D 0.4 mg vs. P4D 4.0 mg (P = 0.0112). For Control vs. P4D 4.0 mg the difference was not within the statistical significance (P = 1.0000)